Trial Profile

A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 30 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ibrutinib (Primary) ; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Melphalan
Indications Diffuse large B cell lymphoma
Focus Therapeutic Use
Acronyms IRONCLAD

27 Dec 2024 Planned End Date changed from 10 May 2025 to 24 Dec 2025.
15 May 2024 Planned End Date changed from 10 May 2024 to 10 May 2025.
15 May 2024 Planned primary completion date changed from 10 May 2024 to 10 May 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com